Merck and Israel’s Maccabi Healthcare to leverage unique real-world database to inform novel health approaches
9 September 2013 | By Merck
Merck and Maccabi Healthcare Services are starting a new, multi-year agreement...
List view / Grid view
News
Novartis data presented at ERS showcases once-daily COPD portfolio and further demonstrates efficacy of Ultibro® Breezhaler® (QVA149)
8 September 2013 | By Novartis
Novartis announced new analyses of data for once-daily Ultibro® Breezhaler®...
Takeda’s new investigational drug Vedolizumab granted priority review status by FDA for ulcerative colitis
6 September 2013 | By Takeda
FDA has granted Priority Review status for the Biologics License Application (BLA) for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis...
Novartis announces global research collaboration with Regenerex, leveraging a novel cell platform to broaden presence in the cell therapy space
6 September 2013 | By
Research collaboration advances company goal to deliver an innovative portfolio of novel cell therapy therapeutics for conditions with a high unmet need...
Capsugel to acquire Bend Research
5 September 2013 | By Capsugel
Capsugel and Bend Research have entered into a definitive agreement for Capsugel to acquire Bend Research as part of its DFS business unit...
The investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoint in Phase III melanoma clinical trial
5 September 2013 | By GlaxoSmithKline
In line with the Independent Data Monitoring Committee’s unanimous recommendation, GSK will continue the DERMA trial until the second co-primary endpoint is assessed...
Merck’s Durham site receives U.S. FDA licensure for varicella bulk
4 September 2013 | By Merck
Merck has received approval from the U.S. FDA to manufacture bulk varicella at the company’s site in Durham...
Novartis marks 30 year anniversary in transplantation and reinforces continued commitment to organ recipients at ESOT congress
4 September 2013 | By Novartis
Novartis reaffirms continued innovation in transplant during anniversary year of breakthrough therapy, ciclosporin...
AstraZeneca initiates Phase III clinical programme for olaparib, a treatment in development for patients with BRCA mutated ovarian cancer
4 September 2013 | By AstraZeneca
As a result of the initiation of this programme, a pre-tax impairment charge of $285 million will be reversed and the asset restored to our balance sheet in the third quarter of 2013...
New data suggests Abbott’s high sensitive troponin test may help doctors more accurately diagnose heart attacks in women
4 September 2013 | By Abbott
Abbott announced promising preliminary results from a study presented at the ESC Congress 2013...
Novartis showcases 39 abstracts highlighting robust respiratory portfolio at ERS 2013
4 September 2013 | By Novartis
Robust efficacy of once-daily Ultibro® Breezhaler® (QVA149) supported by a pooled analysis of the Phase III IGNITE clinical trial program further strengthens evidence for the Ultibro® LABA+LAMA combination for the treatment of COPD patients[1],[2],[3]...
Menomune® is the first quadrivalent meningococcal vaccine prequalified by the WHO
3 September 2013 | By Sanofi
Prequalification makes the vaccine eligible for purchase by United Nations Agencies...
Novartis receives EU approval for Ilaris® in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis
3 September 2013 | By Novartis
Ilaris® is the first interleukin-1 beta (IL-1 beta) inhibitor for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) and is the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection[1]...
Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim’s innovation promise in cardiovascular diseases
3 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announces new plans to expand body of evidence for Pradaxa®...
Amgen and Cytokinetics announce the first presentation of data from Phase 2 ATOMIC-AHF study of Omecamtiv Mecarbil
3 September 2013 | By Amgen
First trial to evaluate cardiac myosin activator in patients with acute heart failure presented at ESC Congress 2013...
